Sarep­ta ce­ments its DMD throne with $1B+ gene ther­a­py deal with mighty Roche

Pop the cham­pagne, Sarep­ta has done it again.

Days be­fore Christ­mas, the keen­ly watched drug­mak­er has clinched a deal with Roche. The large Swiss drug­mak­er is part­ing with a stag­ger­ing $1.15 bil­lion — $750 mil­lion in up­front cash and $400 mil­lion in eq­ui­ty — for the rights to Sarep­ta’s ex­per­i­men­tal gene ther­a­py for Duchenne mus­cu­lar dy­s­tro­phy out­side the Unit­ed States.

Sarep­ta — which will re­tain the US rights to the drug, SRP-9001 — is el­i­gi­ble to re­ceive an­oth­er $1.7 bil­lion in reg­u­la­to­ry and sales mile­stones, in ad­di­tion to roy­al­ties. Roche will al­so shoul­der half the de­vel­op­ment costs for the ther­a­py.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.